BioCentury
ARTICLE | Emerging Company Profile

Radio fusion

How Fusions’ Ac-225 linker improves radiopharmaceutical safety for cancer

June 7, 2018 7:45 PM UTC

Fusion Pharmaceuticals Inc. is improving the safety of radiopharmaceuticals for cancer by using a proprietary linker to label antibodies with the radioisotope actinium-225.

While the newco remains tight-lipped about the linker’s design, SVP of Business Development and U.S. Operations Marc Schwabish told BioCentury the company has shown its linkers improve the safety of IV antibody-radioisotope conjugates over those based on a standard linker -- one widely used in radiopharmaceuticals -- by increasing the excretion of unbound radioactive particles in mice. “With our linker, we have almost four times more of the unbound radioactivity excreted from the body.”...